|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
EP1776383B1
(en)
*
|
2004-07-22 |
2014-08-20 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
|
TWI404727B
(zh)
*
|
2006-01-25 |
2013-08-11 |
荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 |
對偶基因排除
|
|
KR101703299B1
(ko)
|
2007-06-01 |
2017-02-06 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
|
WO2009013620A2
(en)
*
|
2007-06-11 |
2009-01-29 |
Erasmus University Medical Center Rotterdam |
Homologous recombination
|
|
EP2669298A3
(en)
|
2008-05-23 |
2014-02-26 |
Ablexis, LLC |
Single variable immunoglobulin domain comprising VL-DH-JL
|
|
US20100122358A1
(en)
*
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
KR101711222B1
(ko)
|
2008-12-18 |
2017-02-28 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2011072204A1
(en)
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
SG183149A1
(en)
|
2010-02-08 |
2012-09-27 |
Regeneron Pharma |
Common light chain mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
EP2601298B1
(en)
|
2010-08-02 |
2016-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
ES2872081T3
(es)
|
2011-08-05 |
2021-11-02 |
Regeneron Pharma |
Ratones con cadena ligera universal humanizada
|
|
AU2012311286B2
(en)
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
EP4074833A1
(en)
|
2011-10-17 |
2022-10-19 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
SMT201900296T1
(it)
|
2011-12-20 |
2019-07-11 |
Regeneron Pharma |
Topi di catena leggera umanizzata
|
|
GB2502127A
(en)
*
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
NZ703689A
(en)
|
2012-06-12 |
2016-05-27 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
WO2014093908A2
(en)
|
2012-12-14 |
2014-06-19 |
Omt, Inc. |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
|
RS57582B1
(sr)
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
AU2015230938C1
(en)
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
SG10201808083VA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
RU2749674C2
(ru)
|
2015-07-29 |
2021-06-16 |
Аллерган, Инк. |
Антитела против ang-2, содержащие только тяжелую цепь
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
EP3334762A1
(en)
|
2015-08-14 |
2018-06-20 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-07-04 |
Amgen Inc. |
ASGR inhibitors
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
PL3896091T3
(pl)
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
EP3332637A1
(en)
|
2016-12-09 |
2018-06-13 |
Universitätsklinikum Hamburg-Eppendorf |
Vhh-containing heavy chain antibody and production thereof
|
|
CA3050715A1
(en)
|
2017-01-19 |
2018-07-26 |
Open Monoclonal Technology, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
KR102845020B1
(ko)
|
2017-12-28 |
2025-08-12 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
MA51996A
(fr)
|
2018-03-13 |
2021-01-20 |
Smivet B V |
Anticorps à domaine unique se liant à la neurotoxine tétanique
|
|
CN108486125B
(zh)
*
|
2018-03-27 |
2024-01-05 |
重庆金迈博生物科技有限公司 |
一种核酸分子及其在制备人源单域抗体中的应用
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
JP2021525806A
(ja)
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
JP7572861B2
(ja)
|
2018-06-13 |
2024-10-24 |
クリスタル バイオサイエンス インコーポレイテッド |
遺伝子変換による自律型重鎖可変ドメインの改変による抗体の産生
|
|
WO2020052543A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
|
CN113795511B
(zh)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
抗pd-l1双抗体及其用途
|
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
US20220227888A1
(en)
|
2019-06-07 |
2022-07-21 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021154993A1
(en)
*
|
2020-01-28 |
2021-08-05 |
University Of Southern California |
Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
|
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
|
JP7715722B2
(ja)
|
2020-02-28 |
2025-07-30 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗ｃｄ１３７コンストラクト及びその使用
|
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
WO2021247769A1
(en)
|
2020-06-02 |
2021-12-09 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
|
WO2021257679A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
WO2022002038A1
(zh)
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
免疫细胞衔接器多特异性结合蛋白及其制备和应用
|
|
EP4545569A3
(en)
|
2020-06-30 |
2025-10-08 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
CN116193985A
(zh)
*
|
2020-07-13 |
2023-05-30 |
加拿大商木曾路生物科技公司 |
表达重链抗体的转基因动物
|
|
CA3186065A1
(en)
|
2020-07-16 |
2022-01-20 |
Xiaohu FAN |
Cd19 binding molecules and uses thereof
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
IL300121A
(en)
|
2020-07-29 |
2023-03-01 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
IL300505A
(en)
|
2020-08-10 |
2023-04-01 |
Janssen Biotech Inc |
Materials and methods for the production of biologically engineered virus-specific lymphocytes
|
|
CN114134144A
(zh)
*
|
2020-09-04 |
2022-03-04 |
北京仁源欣生生物科技有限公司 |
一种非人哺乳动物或其子代的制备方法及其应用
|
|
PH12023550779A1
(en)
|
2020-09-28 |
2023-11-20 |
Angitia Biomedicines Ltd |
Anti-sclerostin constructs and uses thereof
|
|
JP2023548866A
(ja)
|
2020-10-29 |
2023-11-21 |
インダストリアル ポリマーズ アンド ケミカルズ， インコーポレイテッド |
病原体監視及び不活性化のエアフィルター
|
|
GB202017555D0
(en)
|
2020-11-06 |
2020-12-23 |
Harbour Antibodies Bv |
Antibody-conjugated nanoparticles
|
|
CN116723861A
(zh)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
抗GARP/TGFβ抗体及使用方法
|
|
MX2023006573A
(es)
|
2020-12-03 |
2023-06-19 |
Amgen Inc |
Constructos de inmunoglobulina con multiples dominios de union.
|
|
JP7822400B2
(ja)
*
|
2020-12-09 |
2026-03-02 |
トリアンニ，インコーポレーテッド |
重鎖のみ抗体
|
|
BR112023016706A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
BR112023016713A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
CN116917322A
(zh)
|
2021-02-19 |
2023-10-20 |
沙裴隆有限公司 |
针对pd-l1及cd47的双特异性单域抗体及其用途
|
|
JP2024507958A
(ja)
|
2021-02-26 |
2024-02-21 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
|
|
CN117715933A
(zh)
|
2021-03-05 |
2024-03-15 |
当康生物技术有限责任公司 |
抗vista的构建体及其用途
|
|
WO2022204724A1
(en)
|
2021-03-25 |
2022-09-29 |
Dynamicure Biotechnology Llc |
Anti-igfbp7 constructs and uses thereof
|
|
EP4355785A1
(en)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
|
KR20240163119A
(ko)
|
2022-03-25 |
2024-11-18 |
상하이 헨리우스 바이오테크, 인크. |
항-msln 항체 및 사용 방법
|
|
CN119907674A
(zh)
|
2022-07-22 |
2025-04-29 |
詹森生物科技公司 |
遗传指令向效应免疫细胞的增强转移
|
|
US20260078185A1
(en)
|
2022-09-07 |
2026-03-19 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
EP4512243A1
(en)
*
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
CN122003435A
(zh)
|
2023-09-03 |
2026-05-08 |
科越医药(美国)有限责任公司 |
包含抗因子d部分的多特异性构建体
|
|
WO2025154058A1
(en)
*
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|
|
GB202406483D0
(en)
|
2024-05-09 |
2024-06-26 |
Harbour Antibodies Bv |
Crossing the blood brain barrier to treat diseases of the brain
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20260123608A1
(en)
*
|
2024-08-06 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
|
WO2026075989A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Engineered igg molecules and methods of use thereof
|
|
WO2026086785A1
(en)
|
2024-10-21 |
2026-04-30 |
Shenzhen Wondercel Biotechnology Limited |
Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
|
|
WO2026136279A1
(en)
|
2024-12-16 |
2026-06-25 |
Regeneron Pharmaceuticals, Inc. |
Engineered single domain antibody constructs and methods of use thereof
|